​

Funding Round

Series C - Aardvark Therapeutics

Series C - Aardvark Therapeutics

Investment Firm

Overview

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.

Announced Date

May 09, 2024

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Decheng Capital

Decheng Capital

Decheng Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

11

Investor Name
Participant InvestorCormorant Asset Management
Participant InvestorTetragon Financial Group Limited
Participant InvestorDecheng Capital
Participant InvestorVickers Venture Partners
Participant InvestorLG Technology Ventures

Round Details and Background

Aardvark Therapeutics raised $85000000 on 2024-05-09 in Series C

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 05, 2021
Series B - Aardvark Therapeutics
6-29.0M
Nov 29, 2019
Series A - Aardvark Therapeutics
5-15.0M
May 09, 2024
Series C - Aardvark Therapeutics
13-85.0M

Recent Activity

There is no recent news or activity for this profile.